EOPM PTO 1449 (modified)							Atty. Dkt. No.				Client Ref.		
FORM PTO-1449 (modified)						037003-0280609				2000-30-0154A			
		MAY 1 2 2	G G										
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Applicant: GRILLO-LOPEZ							
						Appln. No.: 09/840,872							
							Filing Date: September 12, 2002						
Date: May	12, 2004	F	Page 1 of 4			Examine	er: Gary B. Nick	ol	Grou	p Ar	t Unit: 1	642	
U.S. PATE	NT DOCUM	MENTS											
Examiner's								Class	Sub			Filing	
Initials*		Number	MM/YYYY	(Family Name of		First Inventor)		İ	Class	Class		Date (if appropriate)	
	AR							 	-		(п арргор	nate)	
•	BR	-		 				 	1		 		
	CR		 	 				 			†		
	DR							 			1		
	ER				•			-	-		1		
	FR												
FOREIGN PA	'	MENTS	·					, le	English		Translat	ion	
_	<u> </u>	Document	Date	Country	Inventor	Name			Abstract			Readily Available	
		Number	MM/YYYY								Availabi	е	
	GR												
	HR								····		<u></u>		
	IR												
	JR									<u></u>			
OTHER (Inclu	ding in this or	der Author, Title, Per	iodical Name, Da	ate, Pertine	nt Pages,	etc.)	·						
	KR	Blaney SM et al., "Neoplastic meningitis: diagnosis and treatment considerations," <i>Med Oncol</i> , 2000, 17: 151-162.											
	LR	Cokgor I et al., "Current options for the treatment of neoplastic meningitis," <i>J Neurooncol</i> , 2002, 60: 79-88.											
	MR	Harjunpaa A et al., "Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma," Leuk Lymphoma, 2001, 42: 731-738.											
	NR	Pels H et al., "Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature," <i>Onkologie</i> , 2003, 26: 351-354.											
	OR	Rubenstein JL compartment,"				for CNS	lymphomas:	targetin	g the	lept	omenin	gea	
	PR												
	QR									***	-		
	RR						- 11						
	SR	- 									,		
	TR												
	UR										<u> </u>		
Evaminas	<u> </u>	<u> </u>				Doto C-	nsidered:						
Examiner						Juale C0	HSIUEIEU.						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.